These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7024129)

  • 1. Lack of greater seroconversion of rhesus monkeys after subcutaneous inoculation of dengue type 2 live-virus vaccine combined with infection-enhancing antibodies.
    Kraiselburd EN; Lavergne JA; Woodall JP; Kessler MJ; Meier G; Chiriboga J; Moore CG; Sather GE; Pomales A; Maldonado E; Rivera R
    Infect Immun; 1981 Aug; 33(2):389-94. PubMed ID: 7024129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue-2 vaccine: viremia and immune responses in rhesus monkeys.
    Scott RM; Nisalak A; Eckels KH; Tingpalapong M; Harrison VR; Gould DJ; Chapple FE; Russell PK
    Infect Immun; 1980 Jan; 27(1):181-6. PubMed ID: 6766903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
    Kochel TJ; Raviprakash K; Hayes CG; Watts DM; Russell KL; Gozalo AS; Phillips IA; Ewing DF; Murphy GS; Porter KR
    Vaccine; 2000 Jul; 18(27):3166-73. PubMed ID: 10856796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.
    Halstead SB
    J Infect Dis; 1979 Oct; 140(4):527-33. PubMed ID: 117061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
    Men R; Bray M; Clark D; Chanock RM; Lai CJ
    J Virol; 1996 Jun; 70(6):3930-7. PubMed ID: 8648730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantity of dengue virus required to infect rhesus monkeys.
    Kraiselburd E; Gubler DJ; Kessler MJ
    Trans R Soc Trop Med Hyg; 1985; 79(2):248-51. PubMed ID: 2860743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies.
    Marchette NJ; Dubois DR; Larsen LK; Summers PL; Kraiselburd EG; Gubler DJ; Eckels KH
    Am J Trop Med Hyg; 1990 Aug; 43(2):212-8. PubMed ID: 1975159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.
    Eckels KH; Dubois DR; Summers PL; Schlesinger JJ; Shelly M; Cohen S; Zhang YM; Lai CJ; Kurane I; Rothman A
    Am J Trop Med Hyg; 1994 Apr; 50(4):472-8. PubMed ID: 8166355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue virus vaccine studies in Puerto Rico: a review.
    Kraiselburd E
    P R Health Sci J; 1987 Apr; 6(1):27-9. PubMed ID: 3615798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
    Angsubhakorn S; Yoksan S; Pradermwong A; Nitatpattana N; Sahaphong S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):554-9. PubMed ID: 7777925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.